Virus del Papiloma humano / Human Papilloma virus (HPV)

José G. Sanabria Negrín

Texto completo:

PDF HTML

Resumen

Con el objetivo de actualizar la información existente sobre el Virus del Papiloma Humano (VPH) se realizó una revisión bibliográfica de artículos basados en la evidencia de nivel I-II. Fundamentalmente fueron revisados los publicados en la biblioteca Cochrane, Dynamed, Evidence-Based Medicine Updates, New England Journal of Medicine, J Clinical Oncology, Medscape, PubMed, artículos de la Agencia Internacional del Cáncer de Francia, y HPV Today, en inglés, francés, portugués o español, de los últimos 5 años, y se hace referencia a artículos originales de importancia de años anteriores. Se revisaron los siguientes aspectos: Definiciones, epidemiología, etiología: Virus del Papiloma Humano, factores de riesgo, clínica de la infección por el VPH, implicación clínica, pesquisaje de masas, tratamiento, prevención primaria y secundaria; y problemas sociales derivados. La infección por el VPH es sexualmente transmitida, por lo tanto es prevenible, y puede ser curable. Es un virus ADN que necesita de un epitelio para su replicación y completar su ciclo vital. La expresión de sus genes constituyentes varía dentro del epitelio, y de una parte del epitelio a otra, dependiendo del tipo de lesión. Se ha detectado la infección desde la infancia, aún sin relaciones sexuales, para llegar a un clímax alrededor de los 30 años, para luego decrecer. Las alternativas actuales son la prevención primaria mediante el uso de anticonceptivos de barrera, el uso de las vacunas profilácticas, y después que está instaurada la infección las vacunas terapéuticas que se están desarrollando. En todos los aspectos se pueden detectar problemas sociales, desde el diagnóstico con el peso de ansiedad, la carga social que proporciona la infección y las consecuencias que de ella derivan.

Palabras clave: virus, papiloma, enfermedades sexualmente transmisibles/prevención, clínica médica.

ABSTRACT

Aimed at updating the current information on Human Papillomavirus (HPV) evidence-based articles and papers about levels I-II were reviewed. The articles and papers browsed on line were published in: Cochrane, Dynamed, Evidence-based Medicine Update, New England Journal of Medicine, J Clinical Oncology, Medscape, PubMed, IARC and Human Papilloma Virus Today, in English, French, Portuguese or Spanish, from the last 5 years; taking also as reference important original articles from previous years. Terms used for the search were: definitions, epidemiology, etiology, HPV, risk factors, clinical features of the HPV infection, clinical implications, mass screening, treatment, primary/secondary prevention and social repercussion. HPV is a sexually-transmitted infection; thus it is preventable and curable. HPV is a DNA virus needing for an epithelium for its replication and to accomplish its vital cycle. The expression of the genes varies inside the epithelial tissue, and from one part of it to the other depending on the type of lesion. Infection is detected from the childhood, even without sexual intercourse, reaching a climax around 30 years old, and then decreasing. The current alternatives are: the primary prevention by means of the use of barrier methods of contraception and the prophylactic vaccines; mass screening and developing-therapeutic vaccines are used after the infection. In every step of the diagnosis and treatment of the disease social problems may arise from the anxiety burden, the infection and its consequences. A discussion about all these aspects was carried out.

Key words: virus, papiloma, sexually transmitted diseases/prevention, internal medicine.

Referencias

Centers for Disease Control and Prevention. HPV vaccine questions and answers. Accessed at http://www.cdc.gov/std/hpv/STDFact-HPV-vaccine.htm, January 25, 2007.

Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S4-7 Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18760711

Hopman AH, Kamps MA, Smedts F, Speel EJ, Herrington CS, Ramaekers FC. HPV in situ hybridization: impact of different protocols on the detection of integrated HPV. Int J Cancer 2005 Jun 20; 115(3): 419-28. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15688369

Lupiani Castellanos MP y Fraga Hernández ME. Vacunas del Papiloma Humano: Se amplía el calendario vacunal. Canar Ped.Enero-Abril 2008; 32(1): Disponible en: http://www.comtf.es/pediatria/Bol_2008_1/Papiloma_Humano_vacuna_PLupiani.pdf

Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Res Cancer. 2002 may; 2(5):342-50. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/12044010

Jung WW, Chun T, Sul D, Hwang KW, Kang HS, Lee DJ, Han IK. Strategies against human papillomavirus infection and cervical cancer. J Microbiol. 2004 Dec; 42(4):255-66. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15650698

Castro-Jiménez Miguel Ángel, Vera-Cala Lina María, Posso-Valencia Héctor Jaime. Epidemiología del cáncer de cuello uterino: estado del arte. Rev Colomb Obstet Ginecol [serial on the Internet]. 2006 Sep [cited]; 57(3): 182-189. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0034-74342006000300006&lng=en

Burchell AN,Winer RL, De Sanjosé S, Franco E. Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006; 24 (Suppl) 3:52-61

Baseman JG, Koutsky LA. The epidemiology of human Papillomavirus infections. J Clin Virol. 2005 Mar;32 Suppl 1:S16-24. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15753008

Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 2004 Jan; 4(1):46-54. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/14704767

Doorbar J. Eventos del ciclo vital del VPH y selección de biomarcadores. HPV Today. Feb 13, 2007; No 10: Disponible en: http://www.seap.es/bibliografia/HPVToday/HPVToday010SEAP.pdf

Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, et al.. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005 Sep; 366(9490):991-8: Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16168781

Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, Sherman ME, Rodriguez AC, Castle PE, Morales J, Alfaro M, Wright T, Chen S, Clayman B, Burk RD, Viscidi RP. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer. 2003 Oct 6;89(7):1248-54.

Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students. Am J Epidemiol 2003; 157 (3): 218-226. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/12543621

Dailard C. HPV in the United States and Developing Nations: A Problem Of Public Health or Politics? The Guttmacher Report on public policy. 2003 Aug; 6(3): Disponible en: http://www.guttmacher.org/pubs/tgr/06/3/gr060304.html

Syrjanen S, Shabalova I, Petrovichev N, Podistov J, Ivanchenko O, Zakharenko S, Nerovjna R, etr al. Age-specific incidence and clearance of high-risk human papillomavirus infections in women in the former Soviet Union. Int J STD AIDS. 2005 Mar;16(3):217-23. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15835076

Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, Koutsky LA. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005 Mar 1; 191(5):731-8. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15688287

Denis F, Hanz S, Alain S. Clearance, persistence and recurrence of HPV infection. Gynecol Obstet Fertil. 2008 Apr; 36(4):430-40. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18417407

Castle PE. Jeronimo J, Schiffman M, Herrero Ro, Rodríguez AC, Bratti MC, et al. Age-Related Changes of the Cervix Influence Human Papillomavirus Type Distribution. Cancer Res 2006; 66(2): 1218-24. Disponible en: http://cancerres.aacrjournals.org/cgi/content/full/66/2/1218

Hwang HS, Park M, Lee SY, Kwon KH, Pang MG. Distribution and prevalence of HPV genotypes in routine Pap smear of 2470 korean women determined by DNA chip. Cancer Epidemiol Biomarkers Prev. Dec 2004; 13 (12): 2153-6. Disponible en: http://cebp.aacrjournals.org/content/13/12/2153.full.pdf

Berlin Grace VM. HPV type 18 is more oncopotent than HPV16 in uterine cervical carcinogenesis although HPV16 is the prevalent type in Chennai, India. Indian J Cancer. 2009 Jul-Sep; 46 (3): 203-207. Disponible en: http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2009;volume=46;issue=3;spage=203;epage=207;aulast=Berlin

Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995; 172(3): 946-54. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/7892889

Banister C. Blair Holladay E, Cribado del VPH. Pruebas de VPH. HPV Today, 2005, Oct; No. 7: 4.

Meisels A, Fortín R. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. Acta Cytol 1976; 20(6): 505-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/1069445

Mathur RS, Mathur SP. Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers. Gynecol Oncol. 2005 Apr;97(1):206-13. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15790460.

Münger K. The role of human papillomaviruses in human cancers. Front Biosci. 2002 Mar 1;7: d641-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/11861215

Shastri SS, Dinshaw K, Amin G, Goswami S, Patil S, Chinoy R, Kane S, Kelkar R, Muwonge R, Mahe C, Ajit D, Sankaranarayanan R. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bull World Health Organ. 2005 Mar;83(3):186-94. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2624199/

Jeronimo J, Castle PE, Herrero R, Burk RD, Schiffman M. HPV testing andvisual inspection for cervical cancer screening in resource-poor regions. International Journal of Gynecology and Obstetrics 83 (2003) 311-313. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/14643047

Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette JM, Cherian J. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007 Aug 4;370(9585):398-406. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17679017

Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, Nouhou H, Sakande B, Wesley R, Somanathan T, Sharma A, Shastri S, Basu P. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer. 2008 Jul 1; 123(1):153-60. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18404671

Sankaranarayanan R. Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organisation 2001; 79(10): 954-62. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/11693978

Sanabria Negrín JG, Salgueiro M, Vólquez C. Incremento de la detección de lesiones del cuello uterino con inspección visual con ácido acético en Puerto Esperanza, Pinar del Río. 2008. Tesis de Especialidad de Primer Grado en MGI. 2009.

IARC Screening Group - cervical cancer research studies. Atlas VIA IARC. Available online In: http://screening.iarc.fr/cervicalindex.php

Ferris DG, Litaker MS, Macfee MS, Miller JA. Remote diagnosis of cervical neoplasia: 2 types of telecolposcopy compared with cervicography. J Fam Pract 2003; 52(4):298-304. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/12681091

Li W; Venkataraman S; Gustafsson U; Oyama JC; Ferris DG; Lieberman RW . Using acetowhite opacity index for detecting cervical intraepithelial neoplasia. Journal Of Biomedical Optics [J Biomed Opt] 2009 Jan-Feb; 14 (1): 14-20. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19256708

Miejer C. El próximo paso en el cribado del cáncer de cuello uterino. HPV Today.2009; Mar 17; 1-3. Disponible en: http://www.hpvtoday.com/hpvtoday-sus/pdf/HPV-Today_17_es.pdf

Hammes LS, Korte JE, Tekmal RR, Naud P, Edelweiss MI, Valente PT, Longatto-Filho A, Kirma N, Cunha-Filho JS. Computer-assisted immunohistochemical analysis of cervical cancer biomarkers using low-cost and simple software. Appl Immunohistochem Mol Morphol. 2007 Dec; 15(4):456-62. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18091391

Meshcheriakova MV; Zakharov IuM; Kurenkov EL. Erythropoietin possible influence on the cellular renovation processes of exocervical epithelium in norm, in case of chronic cervicitis and cervical intraepithelial neoplasia 1 and 2 . Ross Fiziol Zh Im I M Sechenova. 2009 Feb; 95 (2): 143-52. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19368312

Conesa-Zamora P; Doménech-Peris A; Ortiz-Reina S; Orantes-Casado FJ; Acosta-Ortega J; García-Solano J; Pérez-Guillermo M. Immunohistochemical evaluation of ProEx C in human papillomavirus-induced lesions of the cervix. J Clin Pathol; 2009 Feb; 62(2), p. 159-62. Disponible en: http://jcp.bmjjournals.com/content/62/2/159.abstract.

Hengstermann A, D'silva MA, Kuballa P, Butz K, Hoppe-Seyler F, Scheffner M, San José S, Muñoz N. Growth suppression induced by downregulation of E6-AP expression in human papillomavirus-positive cancer cell lines depends on p53. J Virol. 2005 Jul;79(14):9296-300. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15994823

McLaughlin-Drubin ME, Huh KW, Münger K. The Human Papillomavirus Type 16 E7 Oncoprotein Associates with E2F6. Journal of Virology. 2008 Sep; 82 (17): 8695-8705. Disponible en: http://jvi.asm.org/cgi/content/abstract/82/17/8695

Moodley M. Update on pathophysiologic mechanisms of human papillomavirus. Curr Opin Obstet Gynecol. 2005 Feb;17(1):61-4. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15711413

Altekruse SF, Lacev JV Jr, Brinton LA, Gravitt PE, Silverberg SG, Barnes WA Jr et al. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors or cervical adenocarcinoma and squamous cell carcinoma= Northeastern United States. Am J Obstet Gynecol, 2003 Mar; 188 (3): 657-63.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/12634637

Saveria Campo, M. Monografía. Las proteínas de transformación esenciales del VPH: E5, E6 y E7. HPV Today. 2005; Pág. 8.in: http://www.hpv.today.com

Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, Weaver B, Kerndt P, Zenilman J, Hagensee M, Suhr CJ, Weinstock H. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med 2008 Apr 1; 148(7):493. Disponible en: http://www.annals.org/content/148/7/493.full.pdf+html

Lindau ST. Prevalence of high-risk HPV stable in older US women. Obstet Gynecol 2008; 112(5): 979-89. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18978096

Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in United States. JAMA 2007 Feb 28; 297(8): 813. Disponible en: http://jama.ama-assn.org/cgi/content/full/297/8/813

Doerfler D, Bernhaus A, Kottmel A, Sam C, Koelle D, Joura EA. Human papilloma virus infection prior to coitarche. Am J Obstet Gynecol 2009 May; 200(5):487e1. Disponible en: http://www.ajog.org/article/PIIS0002937808024344/fulltext

Sonnex, C. et al. Detection of human papillomavirus DNA on the fingers of patients with genital warts. Sexually Transmitted Infections. October 1999 75(5):317-319. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1758241/

Lee NW, Kim D, Park JT, Kim A. Is the human papillomavirus test in combination with the Papanicolaou test useful for management of patients with diagnoses of atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions? Arch Pathol Lab Med 2001 Nov;125(11):1453-7. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/11698001

Goldie SJ, Kim JJ, Wright TC. Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or More. Obstet Gynecol 2004 Apr; 103(4): 619-31. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15051550

Solomon D. VPH en Cribado y Triaje. Estudio ALTS sobre el Triaje de ASCUS y LSIL. HPV Today. 2004; sep 5: 5. Disponible en: http://www.hpvtoday.com/webDocs/Esp/downloads/HPV/HPVToday05_Esp.pdf

Schiffman M, Khan MJ, Solomon D, Herrero R, Wahcolder S, Hildesheim A, Rodriguez AC, Bratti MC, Wheeler CM, Burk RD, PEG Group; ALTS Group. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005; 97 (2): 147-50. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15657345

Bais AG, Rebolj M, Snijders PJ, de Schipper FA, van der Meulen DA, Verheijen RH, Voorhorst F, van Ballegooijen M, Meijer CJ, Helmerhorst TJ. Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int J Cancer 2005; Aug 10; 116(1):122-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15751045

McCaffery K, Waller J, Forrest S, Cadman L, Szarewski A, Wardle J.Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG. 2004 Dec;111(12):1437-43

Hellsten C, Lindqvist PG, Sjöström K. A longitudinal study of sexual functioning in women referred for colposcopy: a 2-year follow up. BJOG. 2008 Jan; 115(2):205-11 Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17903228

Pitts M. Aspectos psico-sociales del VPH:¿Podrían las vacunas VPH instar a los jóvenes a tener relaciones sexuales sin protección? HPV Today 2007; Feb; No. 10: 7. Disponible en: http://www.hpvtoday.com/webDocs/Esp/downloads/HPV/HPVToday10_Esp.pdf

Stanley MA. Vacunas VPH. Expectativas y realidades. HPV Today, 2003; Mar; No. 2: 8-10. Disponible en: http://www.hpvtoday.com/webDocs/Esp/downloads/HPV/HPVToday02_Esp+add.pdf

Fernández R, Ugueto C. Virus del papiloma humano: tratamiento. Tesis. Caracas; s.n; 31 oct. 1997. 38 p.

Fernández M; Soto Pérez J; Fúster Alfaro F; Steinkoler Paul. Tratamiento de las lesiones por virus del Papiloma humano (PVH) a nivel cérvico-vaginal (criocirugía asociado a 5ïfluoracilo y aciclovir Rev. méd. Costa Rica 1998 oct-dic; 65(545):165-8.

World Health Organization (WHO). Primary Prevention of Cervical Cancer. CAN/85.1. Geneva: WHO (October 3 - November 2, 1985).

Winer RL. ¿Protegen los condones contra el VPH? Punto de vista en HPV Today, 2006, Aug. No. 09: 12. Disponible en: http://www.hpvtoday.com/webDocs/Esp/downloads/HPV/HPVToday09_Esp.pdf

Harper D. El impacto real de las vacunas en los países desarrollados radicará en la reducción del coste total de los programas de cribado. HPV Today 2005; Octubre No 7: 1-3 Disponible en: http://www.hpvtoday.com/webDocs/Esp/downloads/HPV/HPVToday07_Esp.pdf

Muñoz N, Bosch FX, Garnett G, Pattnick J, Sultan C, Watson M. Vacunación preventiva contra enfermedades asociadas al VPH: directrices para un máximo beneficio en la salud europea. HPV Today 2005; Oct No. 7: 6. Disponible en: http://www.hpvtoday.com/webDocs/Esp/downloads/HPV/HPVToday07_Esp.pdf

Cortés Bordoy J, García de Paredes M, Muñoz Zato E, Martinón Torres F, Torné Blade A, et-al. Vacunas profilácticas frente al virus del papiloma humano: Documento de consenso 2008. SEMERGEN. 2009; 35(1):20-8. Disponible en: http://www.semergen.es/semergen/microsites/doc_sanitarios/consenso_vph08.pdf

Koutsky L, For the FUTURE II Study Group. Quadrivalent vaccine against human papi-llomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356(19): 15-27. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17494925

Ault KA; for the Future II Study Group. Efficacy of a prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369(9576): 1861-8.50. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17544766

Garland SM, Hernández-Ávila M, Wheeler CM, Pérez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19): 1928-43.51. Disponible en: http://content.nejm.org/cgi/content/full/356/19/1928

Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369(9580): 2161-70.52. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17602732

Dillner J. Efficacy of quadrivalent HPV vaccination against condylomata and low-grade cervical, vulvar, and vaginal intraepithelial neoplasias. Presented at the 24th International Papillomavirus Conference and Clinical Workshop (IPCCW). Beijing, 3-9 de noviembre de 2007. Oral presentation 5B-04. Disponible en: http://www.semergen.es/semergen/microsites/doc_sanitarios/consenso_vph08.pdf

Kiviat NB, Hawes SE, Feng Q. Screening for cervical cáncer in the Era of the HPV vaccine-The urgent need for both new screening guidelines and new biomarkers. JCNI 2008; March 5; 100 (5): 290-291. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18314471

Chustecka Z. True Hypersensitivity to HPV Vaccine Is Uncommon, Say Australian Researchers. BMJ. Published online before print December 2, 2008

Cabezas Cruz E. Aspectos relacionados con la vacuna contra el virus del Papiloma humano. Rev Cubana Obstet Ginecol[revista en internet] 2008; sept-dic[citado]; 34(3): Disponible en: http://bvs.sld.cu/revistas/gin/vol34_3_08/gin04308.htm

Torrens T. Vacuna terapéutica en Cuba en fase preclínica. 2006. Disponible en: http://www.sld.cu/sitios/cpicm-cmw/temas.php?idv=20839.

Enlaces refback

  • No hay ningún enlace refback.




Copyright (c) 2016 Revista de Ciencias Médicas de Pinar del Río